- NCIt
- C8089
Loading cancer entity…
Loading cancer entity…
Clinical trials
7 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00346164 | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma | completed | Phase 3 | 588 | Children's Oncology GroupNETWORK | 5 | Apr 28, 2022 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT00720174 | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | May 17, 2016 | clinicaltrials |
| NCT01567046 | Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas | completed | — | 70 | Children's Oncology GroupNETWORK | 1 | May 17, 2016 | clinicaltrials |
| NCT00030667 | Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
| NCT00331643 | Ixabepilone in Treating Young Patients With Refractory Solid Tumors | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Apr 28, 2022source: clinicaltrials